IGC Pharma, Inc. made a public disclosure
SEC 8-KRead source ↗
IGC Pharma, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in March.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds13 adding, 11 cuttingOf 2 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 50% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in IGC Pharma, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 56% and a beta of 0.9 against the S&P 500.
- Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.
Latest results
- Earnings per share
- -$0.03 against an average estimate of -$0.02: missed by 50.0%
Price chart
- 1 day0.0%
- 1 week-24.0%
- 1 month-29.6%
- This year-32.1%
- 1 year-52.5%
- 5 years-87.0%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- July 15, 2011
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Announcement
- Agreement
IGC Pharma, Inc. entered a material agreement; sold unregistered shares
SEC 8-KRead source ↗
No model value for IGC Pharma, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value IGC Pharma, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.8%: the 10-year Treasury yield (4.9%) plus a beta of 0.85 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare IGC Pharma, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.10 | −11% | $958000 | −25% |
| Next | −$0.08 | +20% | $958000 | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +11.1% on 90 days ago. In the last 30 days, 0 analysts raised IGC Pharma, Inc.'s forecast and 1 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.09 | −$0.09 |
| 60 days ago | −$0.09 | −$0.09 |
| 30 days ago | −$0.09 | −$0.09 |
| 7 days ago | −$0.10 | −$0.09 |
| Now | −$0.10 | −$0.08 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.02 | −$0.03 | −50.0% |
| Mar 2026 | −$0.02 | −$0.02 | 0.0% |
| Mar 2025 | −$0.02 | −$0.01 | +50.0% |
| Dec 2024 | −$0.03 | −$0.02 | +33.3% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 1.1% of tradable shares
- Days to cover
- 0.94 at average volume
- Short interest, 1 month
- −41% to October 15, 2026
- Held by institutions
- 20% of shares
- Held by insiders
- 9.2% of shares
- Employees
- 70 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| IGC | −37% | −67% | −13% | +21% | −18% | −32% |
| Industry peers (median) | −18% | −49% | −14% | −2% | +9% | −12% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| IGC | 42% | 33% | 58% | 50% | 33% | 27% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| IGC | −68% | −72% | −39% | −52% | −40% | −46% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 99% from October 2, 2018 to October 30, 2026. Getting back needed a 6742% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $0.19 – $0.40
- From 52-week high
- −52.5%
- vs 50-day average
- −29.9%
- vs 200-day average
- −32.0%
- Volatility (1 year)
- 56%
- Beta vs S&P 500
- 0.90
Fundamentals
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Plant and Cannabinoid | $1.3M | ▼ 5.5% |
| Tolling White Labeling Service | $1.2M | ▲ 21.5% |
| Infrastructure | $164,000 | — |
| Wellness and Lifestyle | $113,000 | ▼ 50.4% |
| Other Revenue | $0 | ▼ 100.0% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $1.3M | 99.8% | ▲ 7.6% |
| CO | $2,000 | 0.2% | 0.0% |
| India | $0 | 0.0% | ▼ 100.0% |
From IGC Pharma, Inc.'s 10-K filed June 27, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Who owns it
Funds buying and selling- Reported value
- $1.4M
- Institutions reporting
- 35
- Shares held vs prior quarter
- ▲ 21.3%
- Positions opened / closed
- 6 / 5
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Geode Capital Management, LLC | $239,229 | 879K | 16.7% | ▼ 15.7% |
| Vanguard Capital Management LLC | $221,657 | 815K | 15.5% | ▲ 13.4% |
| Blackrock, Inc. | $191,433 | 704K | 13.4% | 0.0% |
| Advisorshares Investments LLC | $184,547 | 678K | 12.9% | New |
| Citadel Advisors LLC | $118,950 | 437K | 8.3% | New |
| Vanguard Fiduciary Trust Co | $114,080 | 419K | 8.0% | ▲ 0.8% |
| Renaissance Technologies LLC | $77,957 | 287K | 5.5% | ▼ 40.8% |
| State Street Corp | $54,617 | 201K | 3.8% | 0.0% |
| Northern Trust Corp | $46,315 | 170K | 3.2% | ▲ 50.1% |
| Dearborn Partners LLC | $31,779 | 119K | 2.2% | ▲ 100.0% |
| Lawood & Co | $20,400 | 75K | 1.4% | 0.0% |
| Goldman Sachs Group Inc | $17,827 | 66K | 1.2% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not IGC Pharma, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- July 15, 2011
- February 23, 2011
- July 21, 2008
- August 18, 2006
Recent SEC filings
- DEF 14A Proxy statement
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
IGC Pharma, Inc. in brief
- What does IGC Pharma, Inc. do?
- IGC Pharma, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in March.
- What is IGC Pharma, Inc.'s stock ticker?
- IGC Pharma, Inc. trades under the ticker IGC on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are IGC Pharma, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Geode Capital Management, LLC, Vanguard Capital Management LLC and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Follow research on IGC Pharma, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.